Skip to main content
Publications
Masterson D, Triguero-Mas M, Marquez S, Zijlema W, Martinez D , Gidlow C, Smith G, Hurst G, Cirach M, Grazuleviciene R, van den Berg M, Kruize H, Maas J, Nieuwenhuijsen M. Use of the natural outdoor environment in different populations in Europe in relation to access: implications for policy . Int J Environ Res Public Health. 2022 Feb 16;19(4):2226. doi: 10.3390/ijerph19042226
O’Connor G, Julvez J, Fernandez-Barres S, Navarrete-Munoz EM, Murcia M, Tardon A, Galan IR, Amiano P, Ibarluzea J, Garcia-Esteban R , Vrijheid M, Sunyer J, Romaguera D. Association of lifestyle factors and neuropsychological development of 4-year-old children . Int J Environ Res Public Health. 2020 Aug 5;17(16):5668. doi: 10.3390/ijerph17165668
Brink M, Schaffer B, Vienneau D, Pieren R, Foraster M , Eze IC, Rudzik F, Thiesse L, Cajochen C, Probst-Hensch N, Rooslie M, Wunderli JM. Self-reported sleep disturbance from road, rail and aircraft noise: exposure-response relationships and effect modifiers in the SiRENE study . Int J Environ Res Public Health. 2019 Oct 29;16(21):4186. doi: 10.3390/ijerph16214186
Keidel D, Anto JM, Basagana X, Bono R, Burte E, Carsin AE , Forsberg B, Fuertes E, Galobardes B, Heinrich J, de Hoogh K, Jarvis D, Kunzli N, Leynaert B, Marcon A, Le Moual N, de Nazelle A, Schindler C, Siroux V, Stempfelet M, Sunyer J, Temam S, Tsai M, Varraso R, Jacquemin B, Probst-Hensch N. The role of socioeconomic status in the association of lung function and air pollution-a pooled analysis of three adult ESCAPE cohorts . Int J Environ Res Public Health. 2019 May 29;16(11):1901. doi: 10.3390/ijerph16111901
Jeong A, Imboden M, Ghantous A, Novoloaca A, Carsin AE , Kogevinas M, Schindler C, Lovison G, Herceg Z, Cuenin C, Vermeulen R, Jarvis D, Amaral AFS, Kronenberg F, Vineis P, Probst-Hensch N. DNA methylation in inflammatory pathways modifies the association between BMI and adult-onset non-atopic asthma . Int J Environ Res Public Health. 2019 Feb 19;16(4):600. doi: 10.3390/ijerph16040600
Nieuwenhuijsen MJ, Gascon M, Martinez D , Ponjoan A, Blanch J, Garcia-Gil MDM, Ramos R, Foraster M , Mueller N, Espinosa A, Cirach M, Khreis H, Dadvand P, Basagana X. Air pollution, noise, blue space, and green space and premature mortality in Barcelona: a mega cohort . Int J Environ Res Public Health. 2018 Oct 30;15(11):2405. doi: 10.3390/ijerph15112405.
Locher B, Piquerez A, Habermacher M, Ragettli M, Roosli M, Brink M, Cajochen C, Vienneau D, Foraster M , Muller U, Wunderli JM. Differences between outdoor and indoor sound levels for open, tilted, and closed windows . Int J Environ Res Public Health. 2018 Jan 18;15(1):149. doi: 10.3390/ijerph15010149
Eze IC, Imboden M, Foraster M , Schaffner E, Kumar A, Vienneau D, Heritier H, Rudzik F, Thiesse L, Pieren R, von Eckardstein A, Schindler C, Brink M, Wunderli J, Cajochen C, Rooslie M, Probst-Hensch N. Exposure to night-time traffic noise, melatonin-regulating gene variants and change in glycemia in adults . Int J Environ Res Public Health. 2017 Dec 1;14(12):1492. doi: 10.3390/ijerph14121492
Yosipovitch G, Reaney M, Mastey V, Eckert L, Nelson L , Clark M , Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis . Poster presented at the 2017 American Academy of Dermatology Annual Meeting; March 4, 2017. Orlando, FL. [abstract] J Am Acad Dermatol. 2017 Jun; 76(6 Suppl 1):AB278. doi: 10.1016/j.jaad.2017.04.1082
Strober B, Gottlieb AB, Sherif B , Mollon P, Gilloteau I, McLeod L , Fox T, Mordin M , Gnanasakthy A , Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept . J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1054
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of-life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5[S1]):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1053
Kimball AB, Rothman KJ , Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results . J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050